intra-arterial tenecteplase administration

Phase 2Small molecule

intra-arterial tenecteplase administration is one of 37 small molecule programs targeting Ischemic stroke. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ischemic StrokeActive, not recruiting

Acute Ischemic Stroke From Large Vessel OcclusionRecruiting

Ischemic StrokePreclinical

Active, not recruiting

Acute Ischemic Stroke From Large Vessel OcclusionPhase 2

Recruiting

Competition

Competitive Landscape

119 competitors in Ischemic Stroke

#DrugCompanyPhaseTrials

Atorvastatin Calcium

Merck & Co.

Phase 3

1 2

Butylphthalide

PPeking Union Medical College Hospital

Phase 3

3 3

PCSK9 Inhibitor

YYun Dai Chen

Phase 3

3 4

Aggrastat

MMedicure

Phase 3

4 5

Zastaprazan

YYonsei University

Phase 3

1 6

Edaravone Dexborneol

SSimcere Pharmaceutical Co., Ltd

Phase 3

10 7

Proamatine

Takeda

Preclinical

2 8

Levaquin

WWim Janssens

Preclinical

3 9

intra-arterial tenecteplase administration

UUniversity of Pennsylvania

Phase 2

1 10

Tylenol

KKenvue Brands

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Acute Ischemic Stroke From Large Vessel Occlusion

NCT06904911

Clinical

Trials by Indication[1]

Ischemic stroke1 trial

Boosting REcanalization of Thrombectomy for Ischemic Stroke by Intra-arterial TNK (BRETIS-TNK)

Completed·GGeneral Hospital of Shenyang Military Region·N/A·NCT04202458·30 enrolled

Acute Ischemic Stroke From Large Vessel Occlusion1 trial

Intra-Arterial Tenecteplase to Improve the Microvascular Hemodynamics After Mechanical Thrombectomy

Recruiting·UUniversity of Pennsylvania·Phase 2·NCT06904911·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for intra-arterial tenecteplase administration. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — intra-arterial tenecteplase administration compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for intra-arterial tenecteplase administration. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Pennsylvania company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Pennsylvania

intra-arterial tenecteplase administration

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Ischemic stroke1 trial

Acute Ischemic Stroke From Large Vessel Occlusion1 trial

References

Drug Info

Quick Facts

Related News